Mikhail Petrov
Interventional Cardiology · Kettering, OHNPI 1952753881
Payments from drug & device makers
Across 79 payments — averaging $30.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$408
- E.r. Squibb & Sons, L.L.C.$291
- AstraZeneca$272
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$236
- Johnson & Johnson$204
- Abiomed$181
- plus $782 from 15 others
What the payments were for
- Travel & lodging$26911%
- Food & beverage$1,92581%
- Education$1798%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 5 | $408 |
| E.r. Squibb & Sons, L.L.C. | 16 | $291 |
| AstraZeneca(2 entities) | 12 | $272 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $236 |
| Johnson & Johnson | 13 | $204 |
| Abiomed | 2 | $181 |
| Abbott | 2 | $178 |
| Esperion Therapeutics, Inc. | 1 | $124 |
| Boehringer Ingelheim | 3 | $73 |
| Advanced Respiratory, Inc | 3 | $62 |
| Biosense Webster, Inc. | 2 | $59 |
| Novartis | 3 | $53 |
| Cardiva Medical, Inc. | 1 | $44 |
| Gilead | 2 | $40 |
| Teleflex LLC | 2 | $33 |
| Amgen | 2 | $29 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| Bayer | 1 | $16 |
| Bard Peripheral Vascular, Inc. | 1 | $16 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SAPIEN 3 Ultra RESILIA$269
- NEXLIZET$124
- NEXLETOL$124
How this compares
$2,373 in reported general payments places this provider in the 30th percentile of 256 interventional cardiology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 26 | $487 |
| ClopidogrelClopidogrel Bisulfate | 30 | $286 |
| Metoprolol Succinate | 17 | $222 |
| Atorvastatin Calcium | 15 | $179 |
| Lisinopril | 11 | $70 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Kettering
- Santiago GarciaCincinnati$3.6M
- Gary AnselColumbus$3.4M
- Dean KereiakesCincinnati$3.4M
- Steven YakubovColumbus$3.2M
- Joseph ChooCincinnati$1.9M
- Carlos Sanchez SotoColumbus$1.7M
- John CheathamColumbus$1.7M
- Brendan DuffyCanton$1.5M
- Timothy HenryCincinnati$1.3M
- Gary FishbeinCenterville$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.